Ser137
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Phosphorylation Site Page:
Ser137 - eIF5B (human)

Site Information
KVEMYSGsDDDDDFN    SwissProt Entrez-Gene
Predicted information: Scansite
Orthologous residues: eIF5B (mouse): S139, eIF5B (rat): S139
Blast this site against: NCBI  SwissProt  PDB 

In vivo Characterization
Methods used to characterize site in vivo: mass spectrometry (3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45, 46, 47, 49, 50, 51, 52)
Disease tissue studied: cervical cancer (13), cervical adenocarcinoma (13), leukemia (46, 47), chronic myelogenous leukemia (46, 47), hepatocellular carcinoma, surrounding tissue (11), lung cancer (5, 43), non-small cell lung cancer (43), multiple myeloma (10), prostate cancer (26, 27, 28, 29), melanoma skin cancer (33, 34, 35, 36)
Relevant cell line - cell type - tissue: 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] (6), 293E (epithelial) (3), 293T (epithelial) (40), A498 (renal) (8), B lymphocyte-blood (10), CL1-0 (pulmonary) (5), CL1-1 (pulmonary) (5), CL1-2 (pulmonary) (5), CL1-5 (pulmonary) (5), GM00130 (B lymphocyte) (7), HCT116 (intestinal) (30), HeLa (cervical) (30, 37, 38, 39, 44), HeLa S3 (cervical) (13), hepatocyte-liver (11), HepG2 (hepatic) (17, 19, 22, 24, 51), HT-29 (intestinal) (52), Jurkat (T lymphocyte) (9, 12, 31, 32, 42, 49), K562 (erythroid) (45, 46, 47), LNCaP (prostate cell) (26, 27, 28, 29), NCI-H1299 (pulmonary) (43), NCI-H2228 (pulmonary) (16, 18, 23, 25), NCI-H3255 (pulmonary) (14, 15, 20, 21), NCI-H460 (pulmonary) (30), platelet-blood (50), skin (33, 34, 35, 36)

Controlled by
Treatments: metastatic potential (5)



References

1

Shiromizu T, et al. (2013) Identification of Missing Proteins in the neXtProt Database and Unregistered Phosphopeptides in the PhosphoSitePlus Database As Part of the Chromosome-Centric Human Proteome Project. J Proteome Res
23312004   Curated Info

2

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

3

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

4

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

5

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

6

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

7

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

8

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

9

(2010) CST Curation Set: 9696; Year: 2010; Biosample: Jurkat; Disease: T cell leukemia; Treatment: pervanadate & calyculin; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-YX(s/t)(phosphorylation)
Curated Info

10

Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90
20230923   Curated Info

11

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

12

(2010) CST Curation Set: 9052; Year: 2010; Biosample: Jurkat; Disease: T cell leukemia; Treatment: pervanadate & calyculin; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

13

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

14

(2009) CST Curation Set: 7415; Year: 2009; Biosample: NCI-H3255; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

15

(2009) CST Curation Set: 7416; Year: 2009; Biosample: NCI-H3255; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

16

(2009) CST Curation Set: 7410; Year: 2009; Biosample: NCI-H2228; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

17

(2009) CST Curation Set: 7408; Year: 2009; Biosample: HepG2; Disease: hepatocellular carcinoma; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

18

(2009) CST Curation Set: 7409; Year: 2009; Biosample: NCI-H2228; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

19

(2009) CST Curation Set: 7407; Year: 2009; Biosample: HepG2; Disease: hepatocellular carcinoma; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

20

(2009) CST Curation Set: 7323; Year: 2009; Biosample: NCI-H3255; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

21

(2009) CST Curation Set: 7322; Year: 2009; Biosample: NCI-H3255; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

22

(2009) CST Curation Set: 7319; Year: 2009; Biosample: HepG2; Disease: hepatocellular carcinoma; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

23

(2009) CST Curation Set: 7320; Year: 2009; Biosample: NCI-H2228; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

24

(2009) CST Curation Set: 7318; Year: 2009; Biosample: HepG2; Disease: hepatocellular carcinoma; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

25

(2009) CST Curation Set: 7321; Year: 2009; Biosample: NCI-H2228; Disease: non-small cell lung cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

26

(2009) CST Curation Set: 7230; Year: 2009; Biosample: LNCaP; Disease: prostate cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

27

(2009) CST Curation Set: 7231; Year: 2009; Biosample: LNCaP; Disease: prostate cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

28

(2009) CST Curation Set: 7232; Year: 2009; Biosample: LNCaP; Disease: prostate cancer; Treatment: PDBu; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

29

(2009) CST Curation Set: 7233; Year: 2009; Biosample: LNCaP; Disease: prostate cancer; Treatment: PDBu; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

30

Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74
19415658   Curated Info

31

(2009) CST Curation Set: 6530; Year: 2009; Biosample: Jurkat; Disease: T cell leukemia; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

32

(2009) CST Curation Set: 6532; Year: 2009; Biosample: Jurkat; Disease: T cell leukemia; Treatment: TPA; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

33

(2009) CST Curation Set: 6431; Year: 2009; Biosample: YA-18; Disease: melanoma skin cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

(2009) CST Curation Set: 6421; Year: 2009; Biosample: YAC-13; Disease: melanoma skin cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

(2009) CST Curation Set: 6423; Year: 2009; Biosample: YAC-14; Disease: melanoma skin cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

(2009) CST Curation Set: 6415; Year: 2009; Biosample: YAC-10; Disease: melanoma skin cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

37

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

38

(2009) CST Curation Set: 6245; Year: 2009; Biosample: HeLa; Disease: cervical adenocarcinoma; Treatment: EGF; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

39

(2009) CST Curation Set: 6244; Year: 2009; Biosample: HeLa; Disease: cervical adenocarcinoma; Treatment: EGF; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-RXX(s/t)(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

40

(2009) CST Curation Set: 6218; Year: 2009; Biosample: 293T; Disease: -; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

41

(2009) CST Curation Set: 5949; Year: 2009; Biosample: NOZ; Disease: gallbladder cancer; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

42

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

43

Tsai CF, et al. (2008) Immobilized metal affinity chromatography revisited: pH/acid control toward high selectivity in phosphoproteomics. J Proteome Res 7, 4058-69
18707149   Curated Info

44

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

45

(2008) CST Curation Set: 4609; Year: 2008; Biosample: K562; Disease: chronic myelogenous leukemia; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

46

(2008) CST Curation Set: 4392; Year: 2008; Biosample: K562; Disease: chronic myelogenous leukemia; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

47

(2008) CST Curation Set: 4393; Year: 2008; Biosample: K562; Disease: chronic myelogenous leukemia; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

48

(2008) CST Curation Set: 3978; Year: 2008; Biosample: REC-1; Disease: lymphoma; Treatment: untreated; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

(2008) CST Curation Set: 3885; Year: 2008; Biosample: Jurkat; Disease: T cell leukemia; Treatment: pervanadate; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

50

Zahedi RP, et al. (2008) Phosphoproteome of resting human platelets. J Proteome Res 7, 526-34
18088087   Curated Info

51

Gevaert K, et al. (2005) Global phosphoproteome analysis on human HepG2 hepatocytes using reversed-phase diagonal LC. Proteomics 5, 3589-99
16097034   Curated Info

52

Kim JE, Tannenbaum SR, White FM (2005) Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res 4, 1339-46
16083285   Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.